English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 2/5 criteria met. Data as of 01/11/2026.
- ❌ Price trend failed
- ⚠️ Mixed growth
- ✅ Debt passed
- ❌ P/E failed
- ✅ Correction passed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: -56.45%
Price change 2019 → 2020: -67.94%
Price change 2020 → 2021: -34.90%
Price change 2021 → 2022: -82.94%
Price change 2022 → 2023: -48.43%
Price change 2023 → 2024: -10.71%
Price change 2024 → 2025: -0.71%
Price change 2025 → 2026: -3.79%
Price change 2026 (year to date): -6.45%
Financial growth
Revenue CAGR (8 years): 3.88%
Earnings CAGR (8 years): N/A
Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.
Debt
Debt-to-equity ratio: 0.05
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -2.93
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 11.55% from the high over 6 months.
Correction between 10.0% and 20.0% (target range).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="ACB" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Aurora Cannabis Inc. | – | 0.18 | – | 🔒 |
| Valerio Therapeutics S.A. | – | 3.67 | −13.5 % | – |
| LNA Santé S.A. | 9.7 | 2.75 | +10.4 % | – |
| Transgene S.A. | – | 0.02 | −20.1 % | – |
| Eurobio Scientific S.A. | 36.8 | 0.09 | +22.1 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by Aurora Cannabis Inc. over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2021 | 174 m | -491 m | -282.8 % | n/a |
| 2022 | 157 m | -1.2 bn | -776.0 % | -9.8 % |
| 2023 | 159 m | -578 m | -364.9 % | +1.1 % |
| 2024 | 191 m | -49.1 m | -25.6 % | +20.8 % |
| 2025 | 243 m | 1.1 m | 0.5 % | +27.0 % |
| 2026 | 227 m | -86.2 m | -38.0 % | -6.6 % |
Amounts converted to USD. Source: published annual accounts, collected on 06/11/2026.
Accounts and financial health
Balance sheet and cash flow published by Aurora Cannabis Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Cash and investments | 301 m | 301 m | 184 m | 185 m | 165 m |
| Total Debt | 226 m | 226 m | 99.8 m | 104 m | 23.9 m |
| Net Debt | -74.5 m | -74.5 m | -79.7 m | -80.3 m | -88.9 m |
| Equity | 491 m | 491 m | 561 m | 564 m | 513 m |
| Total assets | 926 m | 926 m | 840 m | 848 m | 603 m |
| Operating cash flow | -110 m | -85.6 m | -68.5 m | 16.0 m | -13.5 m |
| Investments (capex) | 32.2 m | 6.9 m | 16.8 m | 18.9 m | 22.5 m |
| Free cash-flow | -142 m | -92.5 m | -85.3 m | -2.9 m | -36.1 m |
| Share buybacks | 0 | 0 | 0 | 0 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
Amounts in CAD, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 09/11/2026.
Valuation and competitors
Aurora Cannabis Inc. compared with its sector on the same exchange and with its main competitors.
Direct competitors
| Company | Market cap (USD) | P/E | Net margin |
|---|---|---|---|
| Aurora Cannabis Inc. | 345 m | n/a | 0.5 % |
| Alpha Teknova, Inc. TKNO | 482 m | n/a | -42.6 % |
| Canopy Growth Corporation CGC | 276 m | n/a | -222.3 % |
| Lifecore Biomedical, Inc. LFCR | 241 m | n/a | -30.0 % |
| BioAge Labs, Inc. BIOA | 201 m | n/a | -896.1 % |
| Ironwood Pharmaceuticals, Inc. IRWD | 725 m | 5.6 | 8.1 % |
| Organigram Global Inc. OGI | 124 m | 2.0 | -9.6 % |
| High Tide Inc. HITI | 234 m | n/a | -8.5 % |
| LifeMD, Inc. LFMD | 114 m | n/a | -3.7 % |
| Sector median (Nasdaq) | 20.5 |
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on . Competitors: comparable companies named by the data provider.
Analyst consensus and forecasts
What the financial analysts covering Aurora Cannabis Inc. publish: ratings, price targets and earnings forecasts.
Breakdown of ratings
Price targets: published for companies listed in the United States only.
Track record against expectations: reported EPS above consensus 4 times over the last 12 releases.
Source: ratings and forecasts published by analysts, collected on 07/11/2026. An analyst rating or target is not a guarantee.
Dividends and earnings
Aurora Cannabis Inc.: dividend history, last distributions, stock splits and earnings releases.
No known dividend for this company.
Earnings releases
Next release: 12/11/2026. Expected EPS: -0.03.
| Date | Published EPS | Expected EPS | Surprise |
|---|---|---|---|
| 05/08/2026 | -0.05 | -0.13 | n/a |
| 11/06/2026 | -0.71 | -0.07 | n/a |
| 04/02/2026 | 0.02 | 0.10 | -75.9 % |
| 05/11/2025 | -0.65 | 0.03 | -2,274.8 % |
| 06/08/2025 | -0.19 | 0.18 | -205.6 % |
| 18/06/2025 | -0.24 | 0.11 | -321.1 % |
Stock splits
| Date | Operation |
|---|---|
| 20/02/2024 | reverse split: 1 share for 10 |
| 11/05/2020 | reverse split: 1 share for 12 |
Factual data: ex-dividend history and earnings calendar, as of 05/11/2026. A past dividend does not guarantee the next one.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in Aurora Cannabis Inc.
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 07/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Aurora Cannabis Inc.
What is the Aurora Cannabis Inc. share price?
Latest recorded price: 5.24 USD on 06/11/2026, for a market cap of 345 m USD.
What is the revenue of Aurora Cannabis Inc.?
227 m USD for fiscal year 2026, with net income of -86.2 m USD (net margin -38.0 %).
When does Aurora Cannabis Inc. report its next earnings?
The next release is expected on 12/11/2026. EPS expected by analysts: -0.03.
What do analysts say about Aurora Cannabis Inc.?
Out of 14 analysts: 3 buy or strong buy, 8 hold, 3 sell or strong sell.
Is Aurora Cannabis Inc. stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN CA05156X8504).
How many employees does Aurora Cannabis Inc. have?
1,073 full-time employees according to the latest published profile.
Who runs Aurora Cannabis Inc.?
Miguel Martin is the company's chief executive.